PD-1/PD-L1 Inhibitors May Improve Survival in NPC - Quiz - MDSpire

PD-1/PD-L1 Inhibitors May Improve Survival in NPC

Meta-analysis suggests survival and response benefits alongside notable toxicity in recurrent or metastatic disease

  • By

  • Andrea Surnit

  • April 22, 2026

  • 2 min

Share

Original Source(s)

PD-1/PD-L1 Inhibitors May Improve Survival in NPC

  • by Andrea Surnit

  • April 22, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Medical Oddities: When a Brush Beats a Scalpel

This research roundup has brain drama, bleeding control, skin science, and tiny brushes.